Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waiting for JAK inhibitor safety data

(2022) Tue Wenzel Kragstrup et al.   RMD Open

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

(2022) Silvio Danese et al.   LANCET

Oral surveillance and JAK inhibitor safety: the theory of relativity

(2022) Kevin L. Winthrop et al.   Nature Reviews Rheumatology

Skin cancers under Janus kinase inhibitors: a world health organization drug safety database analysis

(2022) Cédric Jalles et al.   THERAPIE

Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials

(2022) Pedro Mendes-Bastos et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

(2022) Maria Napolitano et al.   Drug Design Development and Therapy

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

(2022) Désirée van der Heijde et al.   RMD Open

Rheumatoid arthritis: Extra-articular manifestations and comorbidities

(2021) Fabiana Assunta Figus et al.   AUTOIMMUNITY REVIEWS

Eczema herpeticum in atopic dermatitis

(2021) Stephan Traidl et al.   ALLERGY

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

(2021) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The safety of JAK-1 inhibitors

(2021) Benjamin Clarke et al.   RHEUMATOLOGY

Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis

(2021) Hannah Wood et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   Arthritis & Rheumatology

Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis

(2021) Ruolin Liu et al.   Cancer Cell International

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

(2021) Gerd R. Burmester et al.   Rheumatology and Therapy

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Comorbidities associated with psoriatic arthritis: Review and update

(2020) Lourdes M. Perez-Chada et al.   CLINICAL IMMUNOLOGY

The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study

(2020) Lingyi Li et al.   RHEUMATOLOGY

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

(2020) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

(2020) T. Bieber et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

(2020) Andrea Rubbert-Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

(2020) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Comorbidities and the impact of atopic dermatitis

(2019) Jonathan I. Silverberg   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

(2019) Josef S Smolen et al.   LANCET

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

(2019) Roy Fleischmann et al.   Arthritis & Rheumatology

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   Arthritis & Rheumatology

Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis

(2019) Jiang-lin Wang et al.   CLINICAL RHEUMATOLOGY

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Treatment guidelines in psoriatic arthritis

(2019) Alexis Ogdie et al.   RHEUMATOLOGY

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

(2018) Mark C Genovese et al.   LANCET

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Gerd R Burmester et al.   LANCET

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

(2018) Josef S. Smolen et al.   JOURNAL OF RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study

(2013) Wei-Sheng Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of Comorbidities in Ankylosing Spondylitis

(2012) James Rosenbaum et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis and Association With Disease Duration and Hospitalization

(2012) Marie E. Holmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION